{"protocolSection": {"identificationModule": {"nctId": "NCT01566149", "orgStudyIdInfo": {"id": "P08212"}, "secondaryIdInfos": [{"id": "MK-0887A-206", "type": "OTHER", "domain": "Merck Study ID"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212)", "officialTitle": "An Open-Label Study to Assess the Safety and Tolerability of Zenhale\u00ae (a Fixed-Dose Combination of Mometasone Furoate/Formoterol Fumarate Delivered by Metered Dose Inhaler) in 40 Subjects With Persistent Asthma (Protocol No. 206-00 [P08212])"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-03"}, "primaryCompletionDateStruct": {"date": "2012-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-03-27", "studyFirstSubmitQcDate": "2012-03-27", "studyFirstPostDateStruct": {"date": "2012-03-29", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-05-28", "resultsFirstSubmitQcDate": "2013-05-28", "resultsFirstPostDateStruct": {"date": "2013-07-29", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-05-09", "lastUpdatePostDateStruct": {"date": "2024-05-24", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to assess the safety, tolerability \\& effectiveness of 2 strengths of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in the treatment of persistent asthma in adults \\& adolescents."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 49, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MF/F 200/10 mcg MDI BID", "type": "ACTIVE_COMPARATOR", "description": "Participants receiving MF/F 200/10 mcg MDI twice daily (BID) for 12 weeks", "interventionNames": ["Drug: Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI"]}, {"label": "MF/F 400/10 mcg MDI BID", "type": "ACTIVE_COMPARATOR", "description": "Participants receiving MF/F 400/10 mcg MDI BID for 12 weeks", "interventionNames": ["Drug: Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI"]}], "interventions": [{"type": "DRUG", "name": "Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI", "description": "Two oral inhalations per dose", "armGroupLabels": ["MF/F 200/10 mcg MDI BID"], "otherNames": ["Zenhale\u00ae", "SCH 418131", "MK-0887A"]}, {"type": "DRUG", "name": "Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI", "description": "Two oral inhalations per dose", "armGroupLabels": ["MF/F 400/10 mcg MDI BID"], "otherNames": ["Zenhale\u00ae", "SCH 418131", "MK-0887A"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With At Least One Adverse Event (AE)", "description": "An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.", "timeFrame": "Up to Week 14"}, {"measure": "Number of Participants With At Least One Drug-Related AE", "description": "A drug-related AE was defined as any AE for which there is reasonable possibility of drug relationship as assessed by the Investigator.", "timeFrame": "Up to Week 14"}, {"measure": "Number of Participants With At Least One Serious AE", "description": "A serious AE was defined as any untoward medical occurrence or effect that at\n\nany dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; and/or cancer.", "timeFrame": "Up to Week 14"}, {"measure": "Number of Participants Who Discontinued From the Study Due to an AE", "description": "An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.", "timeFrame": "Up to Week 12"}], "secondaryOutcomes": [{"measure": "Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 12", "description": "Baseline was defined as the highest FEV1 value of three assessments prior to first dose of study drug. If two (or all three) spirometry efforts had identical FEV1, the FEV1 from the effort with the highest Forced Vital Capacity (FVC) was to be recorded. Week 12 FEV1 was assessed as the morning FEV1 at the end of the dosing interval (trough FEV1). For participants who discontinued prior to Week 12, the FEV1 measurement from the discontinuation visit was to be be carried forward to Week 12 if (and only if) the participant's study medication compliance rate prior to discontinuation was at least 85%.", "timeFrame": "Baseline and Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of asthma of at least 6 months duration\n* Current use of a medium or high daily dose of an inhaled corticosteroid (ICS) (alone or in combination with a long-acting beta agonist \\[LABA\\]) for at least 6 weeks prior to Screening AND must be on a stable asthma regimen (daily dose unchanged) for at least 2 weeks prior to Screening\n* Agrees to change asthma therapy (if changing asthma therapy poses no inherent risk)\n* If female of reproductive potential, agrees to remain abstinent or use 2 acceptable methods of birth control during study participation. Acceptable methods of birth control are: intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, vasectomy, hormonal contraceptive\n\nExclusion Criteria:\n\n* Treatment in the emergency room (for a severe asthma exacerbation), or admitted to the hospital for management of airway obstruction within previous 3 months\n* Any prior ventilator support for respiratory failure secondary to asthma,\n* Upper or lower respiratory tract infection (viral or bacterial) within previous 2 weeks\n* History of a medical condition that, in the investigator's opinion, may interfere with study participation,\n* History of smoking within previous year or a cumulative smoking history of more than 10 pack-years\n* Known allergy to or intolerance of ICSs, LABAs, or any of the ingredients included in the study medications\n* History of use of illicit drugs\n* Inability to correctly use an oral MDI\n* Pregnant, breastfeeding or plans to become pregnant during study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants who were previously on medium-dose asthma medication were assigned to Mometasone Furoate/Formoterol Fumarate (MF/F) 200/10 mcg Metered Dose Inhaler (MDI) twice daily (BID) and participants who were previously on high-dose asthma medication were assigned to MF/F 400/10 mcg MDI BID.", "recruitmentDetails": "Participants were recruited from one study site in Vietnam between March 2012 and September 2012.", "groups": [{"id": "FG000", "title": "MF/F 200/10 mcg MDI BID", "description": "Participants receiving MF/F 200/10 mcg MDI BID for 12 weeks"}, {"id": "FG001", "title": "MF/F 400/10 mcg MDI BID", "description": "Participants receiving MF/F 400/10 mcg MDI BID for 12 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "25"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "23"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Non-compliance with study medication", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "MF/F 200/10 mcg MDI BID", "description": "Participants receiving MF/F 200/10 mcg MDI BID for 12 weeks"}, {"id": "BG001", "title": "MF/F 400/10 mcg MDI BID", "description": "Participants receiving MF/F 400/10 mcg MDI BID for 12 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "49"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "35.4", "spread": "14.48"}, {"groupId": "BG001", "value": "41.2", "spread": "14.91"}, {"groupId": "BG002", "value": "38.3", "spread": "14.84"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "26"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "23"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With At Least One Adverse Event (AE)", "description": "An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.", "populationDescription": "The Full Analysis Set (FAS) population consisted of all participants assigned treatment who received at lease one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Up to Week 14", "groups": [{"id": "OG000", "title": "MF/F 200/10 mcg MDI BID", "description": "Participants receiving MF/F 200/10 mcg MDI BID for 12 weeks"}, {"id": "OG001", "title": "MF/F 400/10 mcg MDI BID", "description": "Participants receiving MF/F 400/10 mcg MDI BID for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "8"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With At Least One Drug-Related AE", "description": "A drug-related AE was defined as any AE for which there is reasonable possibility of drug relationship as assessed by the Investigator.", "populationDescription": "The FAS population consisted of all participants assigned treatment who received at lease one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Up to Week 14", "groups": [{"id": "OG000", "title": "MF/F 200/10 mcg MDI BID", "description": "Participants receiving MF/F 200/10 mcg MDI BID for 12 weeks"}, {"id": "OG001", "title": "MF/F 400/10 mcg MDI BID", "description": "Participants receiving MF/F 400/10 mcg MDI BID for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With At Least One Serious AE", "description": "A serious AE was defined as any untoward medical occurrence or effect that at\n\nany dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; and/or cancer.", "populationDescription": "The FAS population consisted of all participants assigned treatment who received at lease one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Up to Week 14", "groups": [{"id": "OG000", "title": "MF/F 200/10 mcg MDI BID", "description": "Participants receiving MF/F 200/10 mcg MDI BID for 12 weeks"}, {"id": "OG001", "title": "MF/F 400/10 mcg MDI BID", "description": "Participants receiving MF/F 400/10 mcg MDI BID for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants Who Discontinued From the Study Due to an AE", "description": "An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.", "populationDescription": "The FAS population consisted of all participants assigned treatment who received at lease one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Up to Week 12", "groups": [{"id": "OG000", "title": "MF/F 200/10 mcg MDI BID", "description": "Participants receiving MF/F 200/10 mcg MDI BID for 12 weeks"}, {"id": "OG001", "title": "MF/F 400/10 mcg MDI BID", "description": "Participants receiving MF/F 400/10 mcg MDI BID for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 12", "description": "Baseline was defined as the highest FEV1 value of three assessments prior to first dose of study drug. If two (or all three) spirometry efforts had identical FEV1, the FEV1 from the effort with the highest Forced Vital Capacity (FVC) was to be recorded. Week 12 FEV1 was assessed as the morning FEV1 at the end of the dosing interval (trough FEV1). For participants who discontinued prior to Week 12, the FEV1 measurement from the discontinuation visit was to be be carried forward to Week 12 if (and only if) the participant's study medication compliance rate prior to discontinuation was at least 85%.", "populationDescription": "The FAS population consisted of all participants assigned treatment who received at lease one dose of study medication and had at least one efficacy measurement post-dose.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "MF/F 200/10 mcg MDI BID", "description": "Participants receiving MF/F 200/10 mcg MDI BID for 12 weeks"}, {"id": "OG001", "title": "MF/F 400/10 mcg MDI BID", "description": "Participants receiving MF/F 400/10 mcg MDI BID for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "25"}]}], "classes": [{"title": "Baseline FEV1", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.397", "spread": "0.6824", "lowerLimit": "0.006", "upperLimit": "0.214"}, {"groupId": "OG001", "value": "2.215", "spread": "0.6206", "lowerLimit": "-0.051", "upperLimit": "0.153"}]}]}, {"title": "Week 12 FEV1", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.503", "spread": "0.7418"}, {"groupId": "OG001", "value": "2.270", "spread": "0.6041"}]}]}, {"title": "Change from Baseline in FEV1 at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.106", "spread": "0.2892"}, {"groupId": "OG001", "value": "0.054", "spread": "0.2055"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to Week 14", "description": "The FAS population consisted of all participants assigned treatment who received at least one dose of study medication.", "eventGroups": [{"id": "EG000", "title": "MF/F 200/10 mcg MDI BID", "description": "Participants receiving MF/F 200/10 mcg MDI BID for 12 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 5, "otherNumAtRisk": 24}, {"id": "EG001", "title": "MF/F 400/10 mcg MDI BID", "description": "Participants receiving MF/F 400/10 mcg MDI BID for 12 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 25, "otherNumAffected": 8, "otherNumAtRisk": 25}], "otherEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.0)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 25}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.0)", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 25}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.0)", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 25}]}, {"term": "Accidental overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (15.0)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 25}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The PI agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Vietnam"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068656", "term": "Mometasone Furoate"}, {"id": "D000068759", "term": "Formoterol Fumarate"}, {"id": "D000068758", "term": "Mometasone Furoate, Formoterol Fumarate Drug Combination"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M290", "name": "Mometasone Furoate", "asFound": "Tea", "relevance": "HIGH"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Channel", "relevance": "HIGH"}, {"id": "M303", "name": "Mometasone Furoate, Formoterol Fumarate Drug Combination", "asFound": "Cartilaginous", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}